• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nanoform Finland

0.96 EUR+4.95 %21.8, 17.29
3,777 following

NANOFH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+4.95 %
+12.62 %
+22.44 %
+29.58 %
-18.52 %
0.00 %
-40.31 %
-86.30 %
-81.09 %

Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.

Read more
Market cap
81.9M EUR
Turnover
64.21K EUR
Revenue
3.55M
EBIT %
-520.56 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Nanoform small is powerful Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting... Nanoform Finland Plc | Inside Information | August 05, 2026… “We are encouraged by the UK MHRA’s feedback, which provides support for the regulatory strategy of our nanoenzalutamide...
8/5/2026, 9:04 AM
by Latupuikko
15
Setting up that GMP line at a CDMO facility certainly makes sense. Biological compounds in aqueous solutions generally require cold chain storage. Therefore, locating production and nanoformulation in the same facilities reduces issues related to storage and transport. I browsed ...
8/20/2026, 6:47 AM
by jerej
9
Agreed. Sounds pretty good. Here are more details from the report. “To obtain sterile GMP status for our biological technology, we have initiated discussions with several CDMO organizations regarding the potential placement of our technology in one of their existing facilities. The...
8/20/2026, 5:45 AM
by Latupuikko
9
This is a strategically sound choice in this situation. A report with no surprises. Things are proceeding as expected and the cost-cutting measures have been effective. There are already so many prospects here that I would argue the cash position is sufficient to get us across the...
8/20/2026, 5:41 AM
5
Nanoform small is powerful Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the... Nanoform Finland Plc | Company Release | August 20, 2026… Nanoenzalutamide project continues with the communicated multitrack strategy supported by all partners. After a positive...
8/20/2026, 5:25 AM
by Latupuikko
5
In my opinion, comparing these risky growth companies based on their current price doesn’t make sense. Nano’s market cap in the spring was under 40 million. Today it’s around 80 million, and on Thursday, it will likely be somewhere completely different. The additional potential brought...
8/18/2026, 10:29 AM
by Latupuikko
5
Without taking a stance on these three other companies, I see revenue as a poor metric for companies like this that rely on future potential. Regarding the adequacy of the cash position, the company itself has informed that it is sufficient, and the insider purchases in the spring...
8/18/2026, 7:51 AM
by Latupuikko
5
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11.11
2026

Interim report Q3'26

25.2
2027

Annual report '26

Regulatory press release20.08.2026, 07.10

Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the UK, significantly improved cash flow and discussions with CDMOs on sterile GMP for our Biologics technology initiated

Nanoform Finland
Press release06.08.2026, 10.00

Invitation to Nanoform’s Q2 2026 Report Presentation

Nanoform Finland
Regulatory press release05.08.2026, 11.00

Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide

Nanoform Finland

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release10.06.2026, 12.30

Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma

Nanoform Finland
Regulatory press release10.06.2026, 12.30

Nanoform Finland Plc – Manager’s Transactions – Miguel Calado

Nanoform Finland
Regulatory press release10.06.2026, 07.30

Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2026 on remuneration of the Board of Directors

Nanoform Finland
Regulatory press release29.05.2026, 18.10

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key individuals

Nanoform Finland
Regulatory press release19.05.2026, 07.10

Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology

Nanoform Finland
Regulatory press release12.05.2026, 07.00

Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery

Nanoform Finland
Press release05.05.2026, 10.00

Invitation to Nanoform’s Q1 2026 Report Presentation

Nanoform Finland
Regulatory press release21.04.2026, 11.20

Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026

Nanoform Finland
Regulatory press release21.04.2026, 11.20

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc

Nanoform Finland
Regulatory press release02.04.2026, 08.30

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Nanoform Finland
Regulatory press release02.04.2026, 08.30

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Nanoform Finland
Regulatory press release30.03.2026, 20.10

Inside information: Feedback from European Scientific Advice Meeting with Reference Member State Will Delay Submission of European Marketing Authorization Application Planned Initially for May 2026

Nanoform Finland
Regulatory press release19.03.2026, 19.00

Notice to the Annual General Meeting of NANOFORM FINLAND Plc

Nanoform Finland
Regulatory press release02.03.2026, 15.00

Nanoform Finland Plc – Manager’s Transactions – David Rowe

Nanoform Finland
Regulatory press release02.03.2026, 15.00

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Nanoform Finland
Regulatory press release02.03.2026, 15.00

Nanoform Finland Plc – Manager’s Transactions – Christian Jones

Nanoform Finland
Regulatory press release02.03.2026, 15.00

Nanoform Finland Plc – Manager’s Transactions – Edward Hæggström

Nanoform Finland